Evidence map›Paper›PMID 39354326›Full record

ArticleMethods in molecular biology (Clifton, N.J.)2025

Extracting Knowledge from MS Clinical Metabolomic Data: Processing and Analysis Strategies.

Isabel Meister, Julien Boccard, Serge Rudaz

Abstract read
PubMed Publisher
In one paragraph

Article in Methods in molecular biology (Clifton, N.J.), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Isabel MeisterSchool of Pharmaceutical Sciences, University of Geneva, University of Lausanne, Geneva, Switzerland.
Julien BoccardSchool of Pharmaceutical Sciences, University of Geneva, University of Lausanne, Geneva, Switzerland.
Serge RudazSchool of Pharmaceutical Sciences, University of Geneva, University of Lausanne, Geneva, Switzerland. serge.rudaz@unige.ch.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Assessing potential alterations of metabolic pathways using large-scale approaches plays today a central role in clinical research. Because several thousands of mass features can be measured for each sample with separation techniques hyphenated to mass spectrometry (MS) detection, adapted strategies have to be implemented to detect altered pathways and help to elucidate the mechanisms of pathologies. These procedures include peak detection, sample alignment, normalization, statistical analysis, and metabolite annotation. Interestingly, considerable advances have been made over the last years in terms of analytics, bioinformatics, and chemometrics to help massive and complex metabolomic data to be more adequately handled with automated processing and data analysis workflows. Recent developments and remaining challenges related to MS signal processing, metabolite annotation, and biomarker discovery based on statistical models are illustrated in this chapter in light of their application to clinical research.

Indexed as

BiomarkersMass SpectrometryMetabolomicsComputational BiologyHumansMetabolomeSoftwareBiomarkersData analysis, AnnotationData processingMass spectrometryMetabolomics

Identifiers

PMID39354326

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.